Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0010 | Acetylsalicylic acid

Molecular Formula C9H8O4
Molecular Weight 180.16
Structure
State solid
Clearance The clearance rate of acetylsalicylic acid is extremely variable, depending on several factors [A177217]. Dosage adjustments may be required in patients with renal impairment [FDA label]. The extended-release tablet should not be administered to patients with eGFR of less than 10 mL/min [F4405].
Volume of distribution This drug is distributed to body tissues shortly after administration. It is known to cross the placenta. The plasma contains high levels of salicylate, as well as tissues such as spinal, peritoneal and synovial fluids, saliva and milk. The kidney, liver, heart, and lungs are also found to be rich in salicylate concentration after dosing. Low concentrations of salicylate are usually low, and minimal concentrations are found in feces, bile, and sweat [FDA label].
Route of elimination Excretion of salicylates occurs mainly through the kidney, by the processes of glomerular filtration and tubular excretion, in the form of free salicylic acid, salicyluric acid, and, additionally, phenolic and acyl glucuronides [FDA label]. Salicylate can be found in the urine soon after administration, however, the entire dose takes about 48 hours to be completely eliminated. The rate of salicylate is often variable, ranging from 10% to 85% in the urine, and heavily depends on urinary pH. Acidic urine generally aids in reabsorption of salicylate by the renal tubules, while alkaline urine increases excretion [FDA label]. After the administration of a typical 325mg dose, the elimination of ASA is found to follow first order kinetics in a linear fashion. At high concentrations, the elimination half-life increases [FDA label].
Protein binding 50% to 90% of a normal therapeutic concentration salicylate (a main metabolite of acetylsalicylic acid [FDA label]) binds plasma proteins, particularly albumin, while acetylsalicylic acid itself binds negligibly [FDA label]. Acetylsalicylic acid has the ability to bind to and acetylate many proteins, hormones, DNA, platelets, and hemoglobin [FDA label].
Half life The half-life of ASA in the circulation ranges from 13 - 19 minutes. Blood concentrations drop rapidly after complete absorption. The half-life of the salicylate ranges between 3.5 and 4.5 hours [FDA label].
Absorption Absorption is generally rapid and complete following oral administration but absorption may be variable depending on the route, dosage form, and other factors including but not limited to the rate of tablet dissolution, gastric contents, gastric emptying time, and gastric pH [FDA label]. **Detailed absorption information** When ingested orally, acetylsalicylic acid is rapidly absorbed in both the stomach and proximal small intestine. The non-ionized acetylsalicylic acid passes through the stomach lining by passive diffusion. Ideal absorption of salicylate in the stomach occurs in the pH range of 2.15 - 4.10. Intestinal absorption of acetylsalicylic acid occurs at a much faster rate. At least half of the ingested dose is hydrolyzed to salicylic acid in the first-hour post-ingestion by esterases found in the gastrointestinal tract. Peak plasma salicylate concentrations occur between 1-2 hours post-administration [FDA label].
Trade names Aspirin
Description nonsteroidal anti-inflammatory drug (NSAID); non-selective cyclooxygenase (COX) inhibitor; anti-inflammatory and antipyretic

M

A

B

C

N

N02BA71 Acetylsalicylic acid, combinations with psycholeptics


[N02BA] Salicylic acid and derivatives


[N02B] OTHER ANALGESICS AND ANTIPYRETICS


[N02] ANALGESICS


[N] Nervous system

N02BA51 Acetylsalicylic acid, combinations excl. psycholeptics


[N02BA] Salicylic acid and derivatives


[N02B] OTHER ANALGESICS AND ANTIPYRETICS


[N02] ANALGESICS


[N] Nervous system

N02BA01 Acetylsalicylic acid


[N02BA] Salicylic acid and derivatives


[N02B] OTHER ANALGESICS AND ANTIPYRETICS


[N02] ANALGESICS


[N] Nervous system

N02AJ18 Oxycodone and acetylsalicylic acid


[N02AJ] Opioids in combination with non-opioid analgesics


[N02A] OPIOIDS


[N02] ANALGESICS


[N] Nervous system

N02AJ07 Codeine and acetylsalicylic acid


[N02AJ] Opioids in combination with non-opioid analgesics


[N02A] OPIOIDS


[N02] ANALGESICS


[N] Nervous system

N02AJ02 Dihydrocodeine and acetylsalicylic acid


[N02AJ] Opioids in combination with non-opioid analgesics


[N02A] OPIOIDS


[N02] ANALGESICS


[N] Nervous system

M01BA03 Acetylsalicylic acid and corticosteroids


[M01BA] Antiinflammatory/antirheumatic agents in combination with corticosteroids


[M01B] ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION


[M01] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS


[M] Musculoskeletal system

C10BX12 Atorvastatin, acetylsalicylic acid and perindopril


[C10BX] HMG CoA reductase inhibitors, other combinations


[C10B] LIPID MODIFYING AGENTS, COMBINATIONS


[C10] LIPID MODIFYING AGENTS


[C] Cardiovascular system

C10BX08 Atorvastatin and acetylsalicylic acid


[C10BX] HMG CoA reductase inhibitors, other combinations


[C10B] LIPID MODIFYING AGENTS, COMBINATIONS


[C10] LIPID MODIFYING AGENTS


[C] Cardiovascular system

C10BX06 Atorvastatin, acetylsalicylic acid and ramipril


[C10BX] HMG CoA reductase inhibitors, other combinations


[C10B] LIPID MODIFYING AGENTS, COMBINATIONS


[C10] LIPID MODIFYING AGENTS


[C] Cardiovascular system

C10BX05 Rosuvastatin and acetylsalicylic acid


[C10BX] HMG CoA reductase inhibitors, other combinations


[C10B] LIPID MODIFYING AGENTS, COMBINATIONS


[C10] LIPID MODIFYING AGENTS


[C] Cardiovascular system

C10BX04 Simvastatin, acetylsalicylic acid and ramipril


[C10BX] HMG CoA reductase inhibitors, other combinations


[C10B] LIPID MODIFYING AGENTS, COMBINATIONS


[C10] LIPID MODIFYING AGENTS


[C] Cardiovascular system

C10BX02 Pravastatin and acetylsalicylic acid


[C10BX] HMG CoA reductase inhibitors, other combinations


[C10B] LIPID MODIFYING AGENTS, COMBINATIONS


[C10] LIPID MODIFYING AGENTS


[C] Cardiovascular system

C10BX01 Simvastatin and acetylsalicylic acid


[C10BX] HMG CoA reductase inhibitors, other combinations


[C10B] LIPID MODIFYING AGENTS, COMBINATIONS


[C10] LIPID MODIFYING AGENTS


[C] Cardiovascular system

C07FX04 Bisoprolol and acetylsalicylic acid


[C07FX] Beta blocking agents, other combinations


[C07F] BETA BLOCKING AGENTS, OTHER COMBINATIONS


[C07] BETA BLOCKING AGENTS


[C] Cardiovascular system

C07FX03 Metoprolol and acetylsalicylic acid


[C07FX] Beta blocking agents, other combinations


[C07F] BETA BLOCKING AGENTS, OTHER COMBINATIONS


[C07] BETA BLOCKING AGENTS


[C] Cardiovascular system

C07FX02 Sotalol and acetylsalicylic acid


[C07FX] Beta blocking agents, other combinations


[C07F] BETA BLOCKING AGENTS, OTHER COMBINATIONS


[C07] BETA BLOCKING AGENTS


[C] Cardiovascular system

B01AC56 Acetylsalicylic acid, combinations with proton pump inhibitors


[B01AC] Platelet aggregation inhibitors excl. heparin


[B01A] ANTITHROMBOTIC AGENTS


[B01] ANTITHROMBOTIC AGENTS


[B] Blood and blood forming organs

B01AC06 Acetylsalicylic acid


[B01AC] Platelet aggregation inhibitors excl. heparin


[B01A] ANTITHROMBOTIC AGENTS


[B01] ANTITHROMBOTIC AGENTS


[B] Blood and blood forming organs

A01AD05 Acetylsalicylic acid


[A01AD] Other agents for local oral treatment


[A01A] STOMATOLOGICAL PREPARATIONS


[A01] STOMATOLOGICAL PREPARATIONS


[A] Alimentary tract and metabolism

Toxicity Dose Time Species Model Method Action Positive criterion Reference
TRANSMEMBRANE POTENTIAL NR 24hr rat hepatocytes tetramethylrhodamine ethyl ester (TMRE) Negative AC50 (μM) 40
ELECTROPHORETIC UNCOUPLING 278
MEMBRANE POTENTIAL 335.5 µM 30 mins mouse liver mitochondria Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) decrease EC20 36
RESPIRATION > 800 µM 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. decrease EC20 36
RESPIRATION 149.8 µM 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. decrease EC20 36
STATE 2 RESPIRATION 100 nmol/mg mitochondrial protein rat isolated rat liver mitochondria State 2 respiration ( 96-well plate format using a phosphorescent oxygen-sensitive probe MitoXpress) Negative UC50 (nmol/mg mitochondrial protein) 40
STATE 3 RESPIRATION 100 nmol/mg mitochondrial protein rat isolated rat liver mitochondria State 3 respiration ( 96-well plate format using a phosphorescent oxygen-sensitive probe MitoXpress) Negative IC50 (nmol/mg mitochondrial protein) 40
OXYGEN CONSUMPTION RATE (OCR) 1 mM 2 minutes human HepG2 Measurement of OCR Negative EC50 7
ELECTRON TRANSPORT CHAIN decrease 35
ELECTRON TRANSPORT CHAIN decrease 35
ECAR 1 mM 2 minutes human HepG2 Measurement of ECAR Negative EC50 7
LIPID METABOLISM NR 24hr rat hepatocytes LipidTox, for neutral lipid accumulation, to evaluate lipid content. Negative AC50 (μM) 40
GLUTATHIONE METABOLISM NR 24hr rat hepatocytes glutathion depletion: cells were incubated with 50 μM monochlorobimane with 6 μg/ml Hoechst 33342 Negative AC50 (μM) 40
SWELLING > 800 µM 30 mins mouse liver mitochondria swelling assay: Absorbance at 545 nm using a fluorescence multi-well plate reader (CaCl2 (50 µM) was considered as the 100% baseline for the swelling ) increase EC20 36
OXIDATIVE STRESS 5 μmol/ml 24 hours human HepG2 ROS measurement Negative p < 0.05 2
OXIDATIVE STRESS 5 μmol/ml 48 hours human HepG2 ROS measurement Negative p < 0.05 2
OXIDATIVE STRESS 10 μmol/ml 24 hours human HepG2 ROS measurement increase p < 0.05 2
OXIDATIVE STRESS 10 μmol/ml 48 hours human HepG2 ROS measurement increase p < 0.05 2
ROS PRODUCTION NR rat hepatocytes use CM-H2DCFDA to monitor reactive oxygen species Negative AC50 (μM) 40
CYTOCHROME C RELEASE NR 24hr rat hepatocytes cytochrome c release (anti-cytochrome c antibody ) Negative AC50 (μM) 40
ER STRESS-INDUCED NR 24hr rat hepatocytes DNA damage 153 induction (GADD153 antibodies) for ER-stress induced apoptosis Negative AC50 (μM) 40

Target Dose Time Species Model Method Action Positive criterion Reference
NADH:ubiquinone reductase inhibitor 35
NADH:ubiquinone reductase > 800 µM 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. inhibit EC20 36
Succinate dehydrogenase 149.8 µM 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. inhibit EC20 36
Cytochrome c oxidase inhibitor 35
Reactive oxygen species 5 μmol/ml 24 hours human HepG2 ROS measurement Negative p < 0.05 2
Reactive oxygen species 5 μmol/ml 48 hours human HepG2 ROS measurement Negative p < 0.05 2
Reactive oxygen species 10 μmol/ml 24 hours human HepG2 ROS measurement increase p < 0.05 2
Reactive oxygen species 10 μmol/ml 48 hours human HepG2 ROS measurement increase p < 0.05 2
Cytochrome c > 200 µM 30 mins mouse liver mitochondria Cytochrome c release was evaluated using ELISA kit ( 20 µg/ml Alamethicin was used as 100% baseline) release EC20 36

Pictogram Signal Statements Precautionary Statement Codes
Warning

Aggregated GHS information provided by 181 companies from 19 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


Reported as not meeting GHS hazard criteria by 1 of 181 companies. For more detailed information, please visit ECHA C&L website


Of the 18 notification(s) provided by 180 of 181 companies with hazard statement code(s):


H302 (92.22%): Harmful if swallowed [Warning Acute toxicity, oral]


H315 (35%): Causes skin irritation [Warning Skin corrosion/irritation]


H319 (37.78%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]


H335 (33.89%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure


Respiratory tract irritation]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)
Danger

H302: Harmful if swallowed [Warning Acute toxicity, oral]


H319: Causes serious eye irritation [Warning Serious eye damage/eye irritation]


H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]


H360: May damage fertility or the unborn child [Danger Reproductive toxicity]


H370: Causes damage to organs [Danger Specific target organ toxicity, single exposure]


H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]


 P201, P202, P260, P261, P264, P270, P280, P281, P285, P301+P312, P304+P341, P305+P351+P338, P307+P311, P308+P313, P314, P321, P330, P337+P313, P342+P311, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)
Danger

H302: Harmful if swallowed [Warning Acute toxicity, oral]


H316: Causes mild skin irritation [Warning Skin corrosion/irritation]


H319: Causes serious eye irritation [Warning Serious eye damage/eye irritation]


H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]


H360: May damage fertility or the unborn child [Danger Reproductive toxicity]


H371: May cause damage to organs [Warning Specific target organ toxicity, single exposure]


H373: Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]


 P201, P202, P260, P261, P264, P270, P280, P281, P285, P301+P312, P304+P341, P305+P351+P338, P308+P313, P309+P311, P314, P330, P332+P313, P337+P313, P342+P311, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
women TDLo oral 800mg/kg (800mg/kg) American Journal of Emergency Medicine. Vol. 7, Pg. 409, 1989.
man TDLo oral 857mg/kg (857mg/kg) Human Toxicology. Vol. 7, Pg. 161, 1988.
human TDLo oral 2880mg/kg/8W (2880mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 33, Pg. 631, 1983.
infant TDLo oral 120mg/kg (120mg/kg) British Medical Journal. Vol. 1, Pg. 1081, 1979.
child TDLo oral 39mg/kg/13D-I (39mg/kg) liver: "hepatitis (hepatocellular necrosis), diffuse" American Journal of Diseases of Children. Vol. 139, Pg. 453, 1985.
dog LD50 intravenous 681mg/kg (681mg/kg) behavioral: analgesia Archives Internationales de Pharmacodynamie et de Therapie. Vol. 149, Pg. 571, 1964.
dog LD50 oral 700mg/kg (700mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 719, 1971.
guinea pig LD50 oral 1075mg/kg (1075mg/kg) Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 47, Pg. 479, 1958.
man LDLo unreported 294mg/kg (294mg/kg) "Poisoning; Toxicology, Symptoms, Treatments," 2nd ed., Arena, J.M., Springfield, IL, C.C. Thomas, 1970Vol. 2, Pg. 73, 1970.
mouse LD50 unreported 1350mg/kg (1350mg/kg) United States Patent Document. Vol. #5240918,
rat LD50 intraperitoneal 340mg/kg (340mg/kg) Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 62, Pg. 11, 1966.
women TDLo oral 525mg/kg/5D-I (525mg/kg) liver: "hepatitis (hepatocellular necrosis), diffuse" Annals of Internal Medicine. Vol. 80, Pg. 74, 1974.
women TDLo rectal 4550mg/kg (4550mg/kg) Annals of Pharmacotherpy. Vol. 28, Pg. 467, 1994.
human TDLo oral 480mg/kg/7D-I (480mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 25, Pg. 281, 1975.
man TDLo oral 1625mg/kg (1625mg/kg) behavioral: coma Clinical Pediatrics Vol. 24, Pg. 678, 1985.
rabbit LD50 oral 1010mg/kg (1010mg/kg) behavioral: changes in motor activity (specific assay) Gigiena Truda i Professional'nye Zabolevaniya. Labor Hygiene and Occupational Diseases. Vol. 24(3), Pg. 43, 1980.
hamster LD50 oral 3500mg/kg (3500mg/kg) Archives of Toxicology, Supplement. Vol. 7, Pg. 365, 1984.
mouse LD50 subcutaneous 1020mg/kg (1020mg/kg) Chemical and Pharmaceutical Bulletin. Vol. 28, Pg. 1237, 1980.
rat LD50 rectal 790mg/kg (790mg/kg) "Toxicology of Drugs and Chemicals," Deichmann, W.B., New York, Academic Press, Inc., 1969Vol. -, Pg. 67, 1969.
women TDLo oral 480mg/kg/5D-I (480mg/kg) kidney, ureter, and bladder: "changes in tubules (including acute renal failure, acute tubular necrosis)" New England Journal of Medicine. Vol. 296, Pg. 418, 1977.
human TDLo oral 669mg/kg/11D (669mg/kg) liver: liver function tests impaired American Journal of Hospital Pharmacy. Vol. 35, Pg. 330, 1978.
human TDLo oral 1050mg/kg/14D (1050mg/kg) vascular: other changes Clinical Pharmacology and Therapeutics Vol. 67, Pg. 530, 2000.
mouse LD50 intraperitoneal 167mg/kg (167mg/kg) United States Patent Document. Vol. #4376771,
mouse LD50 oral 250mg/kg (250mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 5, Pg. 572, 1955.
mammal (species unspecified) LD50 oral 1750mg/kg (1750mg/kg) Indian Journal of Medical Research. Vol. 81, Pg. 621, 1985.
man TDLo oral 13036mg/kg/5Y (13036mg/kg) Annals of Internal Medicine. Vol. 126, Pg. 665, 1997.
child TDLo oral 10mg/kg/1D-I (10mg/kg) Clinical Toxicology. Vol. 18, Pg. 247, 1981.
rat LD50 oral 200mg/kg (200mg/kg) "Toxicology of Drugs and Chemicals," Deichmann, W.B., New York, Academic Press, Inc., 1969Vol. -, Pg. 67, 1969.
child LDLo oral 104mg/kg (104mg/kg) Lancet. Vol. 2, Pg. 809, 1952.

  • Acute coronary syndrome

  • Acute myocardial infarction

  • Angina pectoris

  • Angina unstable

  • Body temperature increased

  • Bursitis

  • Cardiac disorder

  • Cerebral infarction

  • Cerebrovascular accident

  • Dysmenorrhoea

  • Embolism venous

  • Fracture

  • Headache

  • Inflammation

  • Influenza

  • Injury

  • Ligament sprain

  • Migraine

  • Multiple fractures

  • Musculoskeletal disorder

  • Myocardial infarction

  • Myositis

  • Nasopharyngitis

  • Neck pain

  • Neuralgia

  • Osteoarthritis

  • Pain

  • Phonophobia

  • Photophobia

  • Rheumatic fever

  • Rheumatoid arthritis

  • Rhinitis

  • Sensitisation

  • Spondylitis

  • Spondyloarthropathy

  • Synovitis

  • Toothache

  • Transient ischaemic attack

    • (non-d)Acetylsalicylic Acid-d3 11126-35-5 156865-15-5
    170197-EP2275413A1 170197-EP2287156A1 1777-EP2269989A1
    1777-EP2269990A1 1777-EP2272825A2 1777-EP2275420A1
    1777-EP2277865A1 1777-EP2280008A2 1777-EP2281563A1
    1777-EP2281815A1 1777-EP2281818A1 1777-EP2292227A2
    1777-EP2295055A2 1777-EP2298764A1 1777-EP2298765A1
    1777-EP2298768A1 1777-EP2298776A1 1777-EP2305219A1
    1777-EP2305260A1 1777-EP2305640A2 1777-EP2305652A2
    1777-EP2308510A1 1777-EP2311453A1 1777-EP2314590A1
    1777-EP2314593A1 1777-EP2316459A1 1777-EP2371811A2
    186947-EP2270113A1 186947-EP2272935A1 1oxr
    2-(Acetyloxy)-benzoic acid 2-(Acetyloxy)benzoic acid 2-(acetyloxy)benzoate
    2-Acetoxybenzenecarboxylic acid 2-Acetoxybenzoate 2-Acetoxybenzoic acid
    2-Acetoxybenzoic acid 2-Acetylsalicyclic acid 2-Carboxyphenyl acetate
    2-acetoxy benzoic acid 2-acetyloxybenzoic acid 24189-EP2295409A1
    24189-EP2314590A1 4-10-00-00138 (Beilstein Handbook Reference) 50-78-2
    6474-EP1441224A2 6474-EP2272832A1 6474-EP2275420A1
    6474-EP2277861A1 6474-EP2277875A2 6474-EP2298757A2
    6474-EP2298764A1 6474-EP2298765A1 6474-EP2314585A1
    8-hour Bayer 99512-66-0 A 5376
    A.S.A A.S.A. A.S.A. empirin
    AB00051918-08 AB00051918_09 AB00051918_10
    AB1003266 AC 5230 ACETYLSALICYLIC ACID
    ACMC-209kpz AI3-02956 AIN
    AKOS000118884 ANW-31125 ASA
    ASA Acenterine Acesal
    Acesan Acetard Aceticyl
    Acetilsalicilico Acetilum acidulatum Acetisal
    Acetonyl Acetophen Acetosal
    Acetosalic acid Acetosalin Acetoxybenzoic acid
    Acetylin Acetylsal Acetylsalicyclic acid
    Acetylsalicylate Acetylsalicylic Acid 1.0 mg/ml in Acetonitrile Acetylsalicylic acid for peak identification, European Pharmacopoeia (EP) Reference Standard
    Acetylsalicylic acid, 99% Acetylsalicylic acid, >=99% Acetylsalicylic acid, >=99.0%
    Acetylsalicylic acid, BioReagent, plant cell culture tested, >=99.0% Acetylsalicylic acid, European Pharmacopoeia (EP) Reference Standard Acetylsalicylic acid, Vetec(TM) reagent grade, >=99%
    Acetylsalicylic acid, analytical standard Acetylsalicylic acid-carboxy-14c AcetylsalicylicAcid
    Acetylsalicylsaeure Acetylsalicylsaure Acetylsalicylsaure [German]
    Acetylsalycilic acid Acetyonyl Acetysal
    Acetysalicylic acid Acide acetylsalicylique Acide acetylsalicylique [French]
    Acido O-acetil-benzoico Acido O-acetil-benzoico [Italian] Acido acetilsalicilico
    Acido acetilsalicilico [Italian] Acidum acetylsalicylicum Acimetten
    Acisal Acylpyrin Adiro
    Aloxiprimum Arthritis Pain Formula Maximum Strength (Salt/Mix) Asacard
    Asagran Asaphen Asatard
    Ascoden-30 Ascolong Ascriptin (Salt/Mix)
    Aspalon Aspalon (JAN) Aspec
    Aspergum Aspir-Mox Aspirdrops
    Aspirin Aspirin Aspirin (Acetyl Salicylic Acid), Pharmaceutical Secondary Standard
    Aspirin (JP17/USP) Aspirin USP (2080B) Aspirin USP (3080)
    Aspirin USP-26 Aspirin [BAN:JAN] Aspirin [USP:BAN:JAN]
    Aspirin form II Aspirin, British Pharmacopoeia (BP) Reference Standard Aspirin, United States Pharmacopeia (USP) Reference Standard
    Aspirin, meets USP testing specifications Aspirin,(S) AspirinTest2
    Aspirina 03 Aspirine Asprin
    Aspro Aspro Clear Aspropharm
    Asteric Azetylsalizylsaeure Azetylsalizylsaure
    BAY-1019036 BBL005469 BCP21790
    BDBM22360 BIDD:GT0118 BRN 0779271
    BSYNRYMUTXBXSQ-UHFFFAOYSA-N Bay E4465 Bay-e-4465
    Bayer Bayer Aspirin 8 Hour Bayer Buffered
    Bayer Children's Aspirin Bayer Enteric 325 mg Regular Strength Bayer Enteric 500 mg Arthritis Strength
    Bayer Enteric 81 mg Adult Low Strength Bayer Extra Strength Aspirin for Migraine Pain Bayer Plus
    Benaspir Benzoic acid, 2-(acetyloxy)- Benzoicacid, 2-(acetyloxy)-
    Bi-prin Bialpirina Bialpirinia
    C01405 CAS-50-78-2 CCG-39490
    CCRIS 3243 CHEBI:15365 CHEMBL25
    CS-2001 CTK1G9661 Cardioaspirin
    Cardioaspirina Cemirit Certified Reference Material
    Claradin Clariprin Colfarit
    Colsprin Contrheuma retard D00109
    D41527A7-A9EB-472D-A7FC-312821130549 DB00945 DS-017139
    DSSTox_CID_108 DSSTox_GSID_20108 DSSTox_RID_75372
    DTXSID5020108 Decaten Delgesic
    DivK1c_000555 Dolean pH 8 Duramax
    Durlaza Durlaza ER EC 200-064-1
    ECM EINECS 200-064-1 EU-0100038
    Easprin Easprin (TN) Ecolen
    Ecotrin Empirin Empirin with Codeine
    Empirin with Codeine (Salt/Mix) Endosprin Endydol
    Entericin Enterophen Enterosarein
    Enterosarine Entrophen Epitope ID:114151
    Extren F2191-0068 FT-0655181
    GTPL4139 Globentyl Globoid
    H740 HMS1920E13 HMS2090G03
    HMS2091K13 HMS2233L18 HMS3260G17
    HMS3372N15 HMS3656N14 HMS3715P19
    HMS501L17 HSDB 652 HY-14654
    Helicon IDI1_000555 Idragin
    InChI=1/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12 Istopirin KBio1_000555
    KBio2_001725 KBio2_002271 KBio2_004293
    KBio2_004839 KBio2_006861 KBio2_007407
    KBio3_002149 KBio3_002751 KBioGR_000398
    KBioGR_002271 KBioSS_001725 KBioSS_002272
    KS-00000ULP KSC269M6D Kapsazal
    Kyselina 2-acetoxybenzoova Kyselina 2-acetoxybenzoova [Czech] Kyselina acetylsalicylova
    Kyselina acetylsalicylova [Czech] LP00038 LS-143
    Levius Lopac-A-5376 Lopac0_000038
    MCULE-3199019536 METHANONE,(2-CHLORO-3-PYRIDINYL)CYCLOBUTYL- MFCD00002430
    MLS001055329 MLS001066332 MLS001336045
    MLS001336046 Magnecyl Measurin
    Medisyl Micrainin (Salt/Mix) Micristin
    Miniasal NCGC00015067-01 NCGC00015067-02
    NCGC00015067-03 NCGC00015067-04 NCGC00015067-05
    NCGC00015067-06 NCGC00015067-07 NCGC00015067-08
    NCGC00015067-09 NCGC00015067-10 NCGC00015067-11
    NCGC00015067-12 NCGC00015067-13 NCGC00015067-14
    NCGC00090977-01 NCGC00090977-02 NCGC00090977-03
    NCGC00090977-04 NCGC00090977-05 NCGC00090977-06
    NCGC00090977-07 NCGC00254034-01 NCGC00259666-01
    NCGC00260723-01 NCI60_002222 NINDS_000555
    NSC 27223 NSC-27223 NSC-406186
    NSC-755899 NSC27223 NSC406186
    NSC755899 Neuronika Novid
    Nu-seals Nu-seals aspirin O-Acetylsalicylic acid
    O-Acetylsalicylic acid O-Acetylsalicylic acid PL-2200
    Percodan (Salt/Mix) Percodan Demi (Salt/Mix) Persistin
    Pharmacin Pharmakon1600-01500130 Pirseal
    Polopirin Polopiryna Pravigard PAC (Salt/Mix)
    Premaspin PubChem20190 Q18216
    R16CO5Y76E RTX-012224 Rheumin tabletten
    Rheumintabletten Rhodine Rhonal
    Ronal S-211 SBB015069
    SBI-0050027.P004 SC-18564 SC-61857
    SCHEMBL1353 SMR000059138 SP 189
    SPBio_001838 SPECTRUM1500130 SR-01000075668
    SR-01000075668-1 SR-01000075668-4 SR-01000075668-6
    ST075414 STL137674 STR01551
    SW199665-2 Salacetin Salcetogen
    Saletin Salicylic acid acetate Salicylic acid, acetate
    Salicylic acid, acetyl- Salospir Salycylacetylsalicylic acid
    Solfrin Solprin Solprin acid
    Solpyron Solupsan Soma Compound (Salt/Mix)
    Spectrum2_001899 Spectrum3_001295 Spectrum4_000099
    Spectrum5_000740 Spectrum_001245 Spira-Dine
    St. Joseph St. Joseph Aspirin for Adults Tasprin
    Temperal Toldex Tox21_110076
    Tox21_110076_1 Tox21_202117 Tox21_300146
    Tox21_500038 Triaminicin Triple-sal
    UNII-R16CO5Y76E UNM-0000306102 WLN: QVR BOV1
    XAXA Yasta Z234893989
    ZINC53 ZORprin acetyl salicyclic acid
    acetyl salicylic acid acetyl-salicylic acid acide 2-(acetyloxy)benzoique
    aspirin aspirin (acetylsalicylic acid) aspirin-acetylsalicylic-acid
    cMAP_000006 cid_2244 component of Ascodeen-30
    component of Ascodeen-30 (Salt/Mix) component of Coricidin component of Darvon with A.S.A
    component of Darvon with A.S.A (Salt/Mix) component of Midol component of Persistin
    component of Robaxisal component of St. Joseph Cold Tablets component of Synirin
    component of Zactirin component of Zactirin (Salt/Mix) o-(Acetyloxy)benzoate
    o-(Acetyloxy)benzoic acid o-Acetoxybenzoate o-Acetoxybenzoic acid
    o-Carboxyphenyl acetate o-acetyl-salicylic acid s3017

    DrugBank Name Acetylsalicylic acid
    DrugBank DB00945
    CAS Number 11126-35-5, 156865-15-5, 50-78-2, 52080-78-1, 921943-73-9, 98201-60-6, 99512-66-0
    PubChem Compound 2244
    KEGG Compound ID C01405
    KEGG Drug D00109
    PubChem.Substance 46505803
    ChEBI 15365
    PharmGKB PA448497
    ChemSpider 2157
    BindingDB 22360.0
    TTD DAP000843
    Wikipedia Aspirin
    HET AIN
    DPD 150